المؤلفون: Johnson, Melissa, Sacher, Adrian, Butler, Marcus, Zarour, Hassane, Weber, Jeffrey, Garon, Edward, Carbone, David, Dhar, Arindam, Messina, Cristina, Patel, Roma, Blouch, Kristin, Hoos, Axel, Martin, Anne-Marie

المصدر: Journal for ImmunoTherapy of Cancer ; volume 9, issue Suppl 2, page A423-A423 ; ISSN 2051-1426

مصطلحات موضوعية: Cancer Research, Pharmacology, Oncology, Molecular Medicine, Immunology, Immunology and Allergy

الوصف: Background To address the heterogeneity of response to therapies, the oncology field is moving toward precision medicine (PM), with therapy tailored to a patient‘s disease. Biomarker assessment is now critical when screening for enrollment into clinical studies, such as for T-cell receptor therapies and combination studies, and determining status of a single analyte does not always correlate to clinical benefit. 1 This shift may increase enrollment screen-failure rates due to restrictive eligibility criteria (e.g., biomarker prevalence). For oncology patients, the need for timely treatment does not allow for a sequential, complex, and time-consuming screening process for each individual clinical trial. The design and data from studies such as Lung MAP have emphasized a need to change clinical trial screening. As we begin to target less common genomic and immunotherapy subtypes, comprehensive molecular characterization may lead to rapid delivery of therapies to patients while maximizing the quality of data. 2 The Molecular Disease Characterization Initiative (MDCI; GlaxoSmithKline Study 213299 [ NCT04772053 ]) screens for multiple studies at once by collecting a baseline assessment of disease prior to treatment with different therapeutic modalities, and evaluating the patient‘s tumor and blood genetics. The MDCI creates a platform to accelerate the availability of new therapeutic options for patients through matched investigative and PM clinical trials, while building a scientific database to facilitate the investigation of biological mechanisms underpinning clinical outcomes. Methods This multicenter study enrolls patients (N= 400) with advanced/metastatic malignancies, initially non-small cell lung cancer, to collect biospecimens for broad molecular profiling and examining the expression of specific antigens (e.g. NY-ESO-1, LAGE-1a), immune markers (e.g. ICOS, PD-L1), tumor-infiltrating immune cells, differentially expressed genes, and human leukocyte antigen (HLA). In this single-arm, non-interventional, ...

الإتاحة: https://doi.org/10.1136/jitc-2021-sitc2021.390Test

المؤلفون: Lundqvist, Andreas, van Hoef, Vincent, Zhang, Xiaonan, Wennerberg, Erik, Lorent, Julie, Witt, Kristina, Sanz, Laia Masvidal, Liang, Shuo, Murray, Shannon, Larsson, Ola, Kiessling, Rolf, Mao, Yumeng, Sidhom, John-William, Bessell, Catherine A., Havel, Jonathan, Schneck, Jonathan, Chan, Timothy A., Sachsenmeier, Eliot, Woods, David, Berglund, Anders, Ramakrishnan, Rupal, Sodre, Andressa, Weber, Jeffrey, Zappasodi, Roberta, Li, Yanyun, Qi, Jingjing, Wong, Philip, Sirard, Cynthia, Postow, Michael, Newman, Walter, Koon, Henry, Velcheti, Vamsidhar, Callahan, Margaret K., Wolchok, Jedd D., Merghoub, Taha, Lum, Lawrence G., Choi, Minsig, Thakur, Archana, Deol, Abhinav, Dyson, Gregory, Shields, Anthony, Haymaker, Cara, Uemura, Marc, Murthy, Ravi, James, Marihella, Wang, Daqing, Brevard, Julie, Monaghan, Catherine, Swann, Suzanne, Geib, James

المصدر: Journal for ImmunoTherapy of Cancer ; volume 4, issue S1 ; ISSN 2051-1426

مصطلحات موضوعية: Cancer Research, Pharmacology, Oncology, Molecular Medicine, Immunology, Immunology and Allergy

الإتاحة: https://doi.org/10.1186/s40425-016-0172-7Test

المؤلفون: Sarnaik, Amod, Hall, MacLean, Mullinax, John, Royster, Erica, Richards, Allison, Crago, Georgina, Zager, Jonathan, Vernon, Sondak, Weber, Jeffrey, Pilon-Thomas, Shari

المصدر: Journal for ImmunoTherapy of Cancer ; volume 3, issue S2 ; ISSN 2051-1426

مصطلحات موضوعية: Cancer Research, Pharmacology, Oncology, Molecular Medicine, Immunology, Immunology and Allergy

الإتاحة: https://doi.org/10.1186/2051-1426-3-s2-p49Test

المؤلفون: Weber, Jeffrey, Grob, Jean-Jaques, Margolin, Kim A, Ascierto, Paolo A, Sznol, Mario, Ott, Patrick A, Lejeune, Chantal, de Pril, Veerle, Ruisi, Mary M, Hodi, F Stephen

المصدر: Journal for ImmunoTherapy of Cancer ; volume 3, issue S2 ; ISSN 2051-1426

مصطلحات موضوعية: Cancer Research, Pharmacology, Oncology, Molecular Medicine, Immunology, Immunology and Allergy

الإتاحة: https://doi.org/10.1186/2051-1426-3-s2-p166Test

المؤلفون: Bartell, Heddy, Wolchok, Jedd, Hodi, F Stephen, Liu, Helen, Wojtaszek, Cynthia, Weber, Jeffrey

المصدر: Journal for ImmunoTherapy of Cancer ; volume 3, issue S2 ; ISSN 2051-1426

مصطلحات موضوعية: Cancer Research, Pharmacology, Oncology, Molecular Medicine, Immunology, Immunology and Allergy

الإتاحة: https://doi.org/10.1186/2051-1426-3-s2-p384Test

المؤلفون: Sullivan, Ryan J., Weber, Jeffrey S.

المصدر: Nature Reviews Drug Discovery ; volume 21, issue 7, page 495-508 ; ISSN 1474-1776 1474-1784

مصطلحات موضوعية: Drug Discovery, Pharmacology, General Medicine

الإتاحة: https://doi.org/10.1038/s41573-021-00259-5Test
https://www.nature.com/articles/s41573-021-00259-5.pdfTest
https://www.nature.com/articles/s41573-021-00259-5Test

المؤلفون: Hodi, F Stephen, Ribas, Antoni, Daud, Adil, Hamid, Omid, Robert, Caroline, Kefford, Richard, Hwu, Wen-Jen, Gangadhar, Tara C, Joshua, Anthony M, Hersey, Peter, Weber, Jeffrey, Joseph, Richard W, Zarour, Hassane, Dronca, Roxana, Gammage, Linda, Hille, Darcy, Xue, Dahai, Kang, S Peter, Chun, Patrick, Ebbinghaus, Scot W, Perrone, Andrea, Wolchok, Jedd D

المصدر: Journal for ImmunoTherapy of Cancer ; volume 2, issue S3 ; ISSN 2051-1426

مصطلحات موضوعية: Cancer Research, Pharmacology, Oncology, Molecular Medicine, Immunology, Immunology and Allergy

الإتاحة: https://doi.org/10.1186/2051-1426-2-s3-p103Test

المؤلفون: Weber, Jeffrey M., Staton, Brian, Bunkowfst, Lori, Hutzler, J. Matthew

المصدر: Drug Metabolism and Pharmacokinetics ; volume 33, issue 1, page S68-S69 ; ISSN 1347-4367

مصطلحات موضوعية: Pharmacology (medical), Pharmaceutical Science, Pharmacology

الإتاحة: https://doi.org/10.1016/j.dmpk.2017.11.229Test
https://api.elsevier.com/content/article/PII:S1347436717304603?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1347436717304603?httpAccept=text/plainTest

المؤلفون: Weber, Jeffrey

المساهمون: New York University New York United States

مصطلحات موضوعية: Medicine and Medical Research, Pharmacology, Biochemistry, SKIN CANCER, proteins, inhibition, antibodies, peptides, POLYMORPHONUCLEAR LEUKOCYTES, endoplasmic reticulum, apoptosis, t lymphocytes, antigens, SURVIVAL, MYELOID CELLS, toxicity, mdsc (Myeloid derived suppressor cells), TNR-related apoptosis induced ligand-receptors, melanoma, DS-8372a, inducible nitric oxide synthetase, tgf-B (transforming growth factor beta), major histocompatibility complex, ros (reactive oxygen species), peroxynitrate, quantitative reverse transcription polymerase chain reaction, inositol-requiring enzyme 1, x-box binding protein-1, osteoprotegerin

الوصف: Myeloid-derived suppressor cells (MDSC) are one of the major negative regulators of immune responses in cancer closely associated with negative outcome of PD1 therapy in metastatic melanoma. TRAIL-R DR5 is selectively up- regulated on MDSC. The goal of this study is to test the hypothesis that agonistic TRAIL-DR5 antibody DS-8273a will be well tolerated and augment the clinical efficacy of PD-1 blocking antibody nivolumab by impacting on MDSC. DS-8372a at low doses (4 and 8 mg/kg) was well tolerated with 2 excellent responses in 6 patients and one mixed response; it did not affect populations of MDSC or other myeloid and lymphoid cells, but monocytic MDSC function was augmented. In the first 4 patients we evaluated the response of T cells to melanoma derived pool of overlapping peptides in IFN- ELISPOT assay. In one patient we observed substantial increase in the response to peptides after 3 cycles of treatment. These results are preliminary. Moreover, the dose of antibody was very low to expect substantial responses. We anticipate that next two doses (16 mg/kg and24 mg/kg) with escalation occurring early in October will provide more clear data.

وصف الملف: text/html

العلاقة: http://www.dtic.mil/docs/citations/AD1046087Test

الإتاحة: http://www.dtic.mil/docs/citations/AD1046087Test
http://oai.dtic.mil/oai/oai?&verb=getRecord&metadataPrefix=html&identifier=AD1046087Test

المؤلفون: Hersh, Evan M., O’Day, Steven J., Powderly, John, Khan, Khuda D., Pavlick, Anna C., Cranmer, Lee D., Samlowski, Wolfram E., Nichol, Geoffrey M., Yellin, Michael J., Weber, Jeffrey S.

المصدر: Investigational New Drugs ; volume 29, issue 3, page 489-498 ; ISSN 0167-6997 1573-0646

مصطلحات موضوعية: Pharmacology (medical), Pharmacology, Oncology

الإتاحة: https://doi.org/10.1007/s10637-009-9376-8Test